- Home
- LE vs MNPR Comparison
LE vs MNPR Comparison
Compare LE & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- MNPR
- Stock Information
- Founded
- LE 1963
- MNPR 2014
- Country
- LE United States
- MNPR United States
- Employees
- LE N/A
- MNPR N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- LE Consumer Discretionary
- MNPR Health Care
- Exchange
- LE Nasdaq
- MNPR Nasdaq
- Market Cap
- LE 274.7M
- MNPR 249.5M
- IPO Year
- LE N/A
- MNPR 2019
- Fundamental
- Price
- LE $9.47
- MNPR $37.16
- Analyst Decision
- LE Strong Buy
- MNPR Strong Buy
- Analyst Count
- LE 1
- MNPR 5
- Target Price
- LE $20.00
- MNPR $59.50
- AVG Volume (30 Days)
- LE 131.5K
- MNPR 17.3K
- Earning Date
- LE 06-04-2025
- MNPR 05-13-2025
- Dividend Yield
- LE N/A
- MNPR N/A
- EPS Growth
- LE N/A
- MNPR N/A
- EPS
- LE 0.20
- MNPR N/A
- Revenue
- LE $1,362,935,000.00
- MNPR N/A
- Revenue This Year
- LE $4.26
- MNPR N/A
- Revenue Next Year
- LE $2.67
- MNPR N/A
- P/E Ratio
- LE $47.52
- MNPR N/A
- Revenue Growth
- LE N/A
- MNPR N/A
- 52 Week Low
- LE $8.15
- MNPR $1.72
- 52 Week High
- LE $19.88
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- LE 55.38
- MNPR 47.26
- Support Level
- LE $7.65
- MNPR $32.97
- Resistance Level
- LE $9.47
- MNPR $44.40
- Average True Range (ATR)
- LE 0.44
- MNPR 4.18
- MACD
- LE 0.19
- MNPR -0.68
- Stochastic Oscillator
- LE 94.30
- MNPR 30.74
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.